Overview of Immutep's Stock Decline#
Immutep Limited, a biopharmaceutical company, saw its shares fall by 80% on Friday. This dramatic drop followed the announcement that its TACTI-004 Phase III trial would be discontinued due to a futility analysis.
What Happened in the Trial?#
The Independent Data Monitoring Committee (IDMC), which oversees clinical trials to ensure participant safety and study integrity, recommended stopping the trial. This study was testing a drug called eftilagimod alfa (or "efti") for patients with first-line non-small cell lung cancer. The IDMC concluded that the trial should be halted because the data indicated that it was unlikely to meet its goals of proving the drug's effectiveness.
Company Response and Future Plans#
In light of the trial's discontinuation, Immutep will stop enrolling new patients and will carefully wind down the study, ensuring that all regulatory and ethical obligations are met, including following up with existing patients. CEO Marc Voigt expressed disappointment and surprise at the trial's outcome, especially given the drug's previous performance in other studies. The company is now reviewing all available data to decide on the next steps for the drug's development.
Financial Outlook and Analyst Reactions#
Despite the setback, Immutep indicated that its financial resources, or "cash runway," are expected to last longer than previously anticipated, extending beyond the second quarter of 2027. Analysts have reacted to the news by downgrading the stock. Baird analyst Colleen Kusy changed her rating from Outperform to Neutral, lowering the price target from $7.00 to $1.00. Similarly, Citizens analyst Reni Benjamin downgraded the stock from Market Outperform to Market Perform, eliminating revenue projections for the lung cancer indication. While other clinical trials are still ongoing, analysts predict that Immutep's shares will likely move in line with the broader market until new, significant results are released.